MAPK Pathway

Overview of attention for article published in Frontiers in Pharmacology, April 2022

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (69th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

So far, Altmetric has seen 20 X posts from 11 X users, with an upper bound of 114,243 followers.

Setanaxib (GKT137831) Ameliorates Doxorubicin-Induced Cardiotoxicity by Inhibiting the NOX1/NOX4/Reactive Oxygen Species/MAPK Pathway https://t.co/iyV36NOzCU https://t.co/LBsQY2bulC

RT @NewYorkPass: Setanaxib (GKT137831) Ameliorates Doxorubicin-Induced Cardiotoxicity by Inhibiting the NOX1/NOX4/Reactive Oxygen Species/M…

RT @NewYorkPass: Setanaxib (GKT137831) Ameliorates Doxorubicin-Induced Cardiotoxicity by Inhibiting the NOX1/NOX4/Reactive Oxygen Species/M…

RT @NewYorkPass: Setanaxib (GKT137831) Ameliorates Doxorubicin-Induced Cardiotoxicity by Inhibiting the NOX1/NOX4/Reactive Oxygen Species/M…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 16 additional X posts.